Abstracts tagged "treatment"

Abstract Number: 0729 • ACR Convergence 2021
A Multicenter, Observational, Extension Study Evaluating the Safety, Tolerability, and Efficacy of a Single Lorecivivint Injection in Knee OA Subjects
Ismail Simsek¹, Christopher Swearingen¹, Heli Ghandehari¹, Sarah Kennedy², Jeyanesh Tambiah¹, Yusuf Yazici³ and Nebojsa Skrepnik⁴, ¹Biosplice Therapeutics, Inc., San Diego, CA, ²Biosplice Therapeutics, Inc, San Diego, CA, ³New York University School of Medicine, La Jolla, CA, ⁴Tucson Orthopaedic Institute, Tucson
Background/Purpose: Lorecivivint (LOR), a novel intra-articular (IA) CLK/DYRK inhibitor that modulates Wnt and inflammatory pathways, is in development as a knee osteoarthritis (OA) treatment. To…
Abstract Number: 0730 • ACR Convergence 2021
Safety, Tolerability, and Pharmacokinetics of an Intra-articular Corticosteroid Injection Administered 7 Days Before or After Intra-articular Lorecivivint Injection into the Same Knee of Healthy Volunteers: An Open-Label, Parallel-Arm Study
Amy Halseth¹, Nancy Lane², Sarah Kennedy³, Christopher Swearingen¹, Victor Lopez¹, Ismail Simsek¹, Mark Fineman¹ and Yusuf Yazici⁴, ¹Biosplice Therapeutics, Inc., San Diego, CA, ²University of California Davis, Hillsborough, CA, ³Biosplice Therapeutics, Inc, San Diego, CA, ⁴New York University School of Medicine, La Jolla, CA
Background/Purpose: Knee osteoarthritis (OA) is a painful condition leading to joint damage and impaired function. Intra-articular (IA) corticosteroid injections are frequently prescribed to treat pain.…
Abstract Number: 0778 • ACR Convergence 2021
Autologous Stem Cell Transplantation with CD34-Selected Peripheral Blood Stem Cells in Patients with Treatment-Resistant Juvenile-Onset Systemic Sclerosis
Kathryn Torok¹, Franziska Rosser², Kirsten Rose-Felker¹, Vibha Sood¹, Geoffrey Kurland¹, Adam Olson¹, Meghan Frost¹, Vickie Vandergrift¹, Shawna McIntyre¹, Alisha Maslanka³, Kaila Schollaert-Fitch¹, Jessie Barnum¹ and Paul Szabolcs¹, ¹University of Pittsburgh, Pittsburgh, PA, ²UPMC Children's Hospital of Pittbsurgh, Pittsburgh, PA, ³University of Pittsburgh, Pittsburgh
Background/Purpose: Juvenile-onset systemic sclerosis (jSSc) is a rare autoimmune disease associated with life-threatening multi-organ inflammation and fibrosis. As in adults, jSSc organ involvement includes vascular,…
Abstract Number: 0781 • ACR Convergence 2021
Long-Term Follow-up of Juvenile Localized Scleroderma Patients Treated with Methotrexate-Based Standardized Regimens (Consensus Treatment Plans)
Suzanne Li¹, Aaron Thammavongxay², Maria Ibarra³, Kathryn Torok⁴, Polly Ferguson⁵, C Egla Rabinovich⁶, Robert Fuhlbrigge⁷, Katie Stewart⁸, Elena Pope⁹, Ronald Laxer¹⁰, Sandy Hong¹¹, Thomas Mason¹², Mara Becker¹³, Gloria Higgins¹⁴, Fatma Dedeoglu¹⁵ and for the CARRA Legacy Registry¹⁶, ¹Hackensack Meridian School of Medicine, Joseph M. Sanzari Children's Hospital, West Orange, NJ, ²Bergen Academies, Hackensack, NJ, ³Children's Mercy Hospital, Kansas City, MO, ⁴University of Pittsburgh, Pittsburgh, PA, ⁵University of Iowa Carver College of Medicine, Iowa City, IA, ⁶Duke Childrens Hospital & Health Center, Durham, NC, ⁷University of Colorado, Denver, CO, ⁸UT Southwestern, Dallas, TX, ⁹Hospital for Sick Kids, Toronto, ON, Canada, ¹⁰SickKids, Toronto, ON, Canada, ¹¹University of Iowa Stead Family Children's Hospital, Iowa City, IA, ¹²Mayo Clinic, Rochester, MN, ¹³Duke University Medical Center/Duke Clinical Research Institute, Chapel Hill, NC, ¹⁴Ohio State University, Columbus, OH, ¹⁵Boston Children's Hospital, Boston, MA, ¹⁶Childhood Arthritis and Rheumatology Research Alliance, Milwaukee, WI
Background/Purpose: Juvenile localized scleroderma (jLS) is a rare chronic inflammatory and fibrosing disease associated with a high risk for morbidity in children. Methotrexate (MTX) has…
Abstract Number: 1124 • ACR Convergence 2021
Examining the Relationships Between Treatment and Pain and Physical Function Outcomes in Patients with Osteoarthritis: A Mediation Modeling Approach
Lucy Abraham¹, Robert Dworkin², Dennis C. Turk³, John D. Markman², David A. Williams⁴, Andrew G Bushmakin⁵, Jerry A. Hall⁶, David C. Semel⁷, Joseph C Cappelleri⁵ and Ruoyong Yang⁸, ¹Pfizer Ltd., Tadworth, United Kingdom, ²University of Rochester, Rochester, NY, ³University of Washington, Seattle, WA, ⁴University of Michigan, Ann Arbor, MI, ⁵Pfizer Inc, Groton, CT, ⁶Eli Lilly and Company, Indianapolis, IN, ⁷Pfizer, New York, NY, ⁸Pfizer Inc., New York, NY
Background/Purpose: To better understand the complex relationships between treatment and pain and physical function (PF) outcomes, we investigated a set of mediation models of osteoarthritis…
Abstract Number: 1256 • ACR Convergence 2021
Factors Associated with the Use of Biologic Disease-modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis
Roya Hosseini¹, Souhiela fawaz² and Enrique Seoane-Vazquez², ¹Chapman University School of Pharmacy, Aliso Viejo, CA, ²Chapman University School of Pharmacy, Irvine, CA
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disease characterized by polyarthritis of small and large joints. RA is the second most common type…
Abstract Number: 1529 • ACR Convergence 2021
Effectiveness and Safety of Pegloticase with Concomitant Immunomodulatory Therapy
Huifeng Yun¹, Brian LaMoreaux², Lang Chen³, Stephanie Ledbetter³, Megan Francis-Sedlak², Kenneth Saag³, Ted Mikuls⁴ and Jeffrey Curtis⁵, ¹University of Alabama Birmingham, Birmingham, AL, ²Horizon Therapeutics plc, Deerfield, IL, ³University of Alabama at Birmingham, Birmingham, AL, ⁴University of Nebraska Medical Center, Omaha, NE, ⁵Division of Clinical Immunology and Rheumatology, Department of Medicine, Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Oral urate-lowering therapy (ULT) is one of the primary treatments for gout. Unfortunately, a proportion of patients with advanced gout are resistant to oral…
Abstract Number: 1764 • ACR Convergence 2021
Estimation of the Prevalence of Hydroxychloroquine-Induced Retinopathy in a Cohort of Hydroxychloroquine-Compliant Patients
Kelley Brady, Roberta Alexander, Rory Bloch, Mark Rudolph, Karina Baggiani, Deborah Stimson and Anja Kammensheidt, Exagen Inc., Vista, CA
Background/Purpose: HCQ is an antimalarial drug effective in the treatment of rheumatologic conditions. High blood levels, advanced age, and extended treatment duration are associated with…
Abstract Number: 1815 • ACR Convergence 2021
Randomised, Double-blind, Placebo-controlled Study of Iguratimod in the Treatment of Active Spondyloarthritis
yan li¹, Kunpeng Li¹, Zheng Zhao¹, yanyan wang¹, Jingyu Jin¹, jianglin zhang¹, Jian Zhu¹ and feng huang², ¹First Medical Center, General Hospital of Chinese People's Liberation Army, Beijing, China (People's Republic), ²Chinese PLA General Hospital, Beijing, China (People's Republic)
Background/Purpose: Iguratimod, also known as T-614, is a new type of small molecule compound with anti-inflammatory and immunomodulatory effects; It was listed in China(2011) and…
Abstract Number: 1829 • ACR Convergence 2021
Pharmacological Treatment of Enthesitis – A Systematic Review on the Efficacy of the Available Options
Rita Torres¹, Santiago Manica² and Fernando Santos², ¹Rheumatology Department, Hospital de Egas Moniz, Centro Hospitalar Lisboa Ocidental, Lisbon, Portugal, ²Hospital Egas Moniz, Lisboa, Portugal
Background/Purpose: Enthesitis is a recognized as a hallmark of spondyloarthrtis (SpA), including psoriatic arthritis (PsA). However, it is an underestimated disease domain in both in…
Abstract Number: 0121 • ACR Convergence 2021
The Efficacy of Group Behavioral Activation versus Usual Treatment in Patients with Fibromyalgia and Major Depression
Josefina Duran, Alvaro Verges, Ana Rocío Vázquez-Taboada, Matias Gonzalez and Lydia Gomez-Pérez, Pontificia Universidad Católica de Chile, Santiago, Chile
Background/Purpose: Fibromyalgia (FM) and major depression frequently coexist. Patients with both conditions have a worse prognosis and higher disability, and their treatment options are scarce.…
Abstract Number: 0207 • ACR Convergence 2021
Treatment of Ocular Sarcoidosis: Study of 65 Patients of a Series of 384 Patients from a Single University Hospital
Carmen Álvarez-Reguera¹, Jorge Javier Gaitán-Valdizán¹, Raúl fernández-ramón¹, Rosalia Demetrio-Pablo¹, José Luis Martin-Varillas², Lara Sánchez-Bilbao¹, David Martinez-Lopez¹, Iñigo Gonzalez-Mazon³, Miguel Ángel gonzalez-Gay⁴ and Ricardo Blanco⁵, ¹Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²Hospital Sierrallana, Torrelavega, Spain, ³H. U. Marques de Valdecilla, Santander, Spain, ⁴Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Division of Rheumatology, Hospital Universitario Marqués de Valdecilla; School of Medicine, Universidad de Cantabria, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, ⁵Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Ocular involvement is a relatively frequent and potentially severe complication of sarcoidosis. Oral corticosteroids (OCS) are the first-line treatment. Conventional immunosuppressive agents (cIS) and…
Abstract Number: 0414 • ACR Convergence 2021
Effect of Induction Therapies on Ear, Nose and Throat Involvement in Anti-neutrophil Cytoplasmic Antibody Associated Vasculitis: Results from a Multi-center Cohort Study
Roline Krol¹, Caroline Schaap¹, Paco Welsing¹, Ruth Klaasen², Hilde Remmelts², Chris Hagen², Franka van Reekum¹, Marloes Heijstek¹ and Julia Spierings¹, ¹University Medical Center Utrecht, Utrecht, Netherlands, ²Meander Medical Center, Amersfoort, Netherlands
Background/Purpose: Up to 87% of patients with anti-neutrophil cytoplasmic antibody (ANCA)- associated vasculitis (AAV) have ear, nose and throat (ENT) involvement, which can lead to…
Abstract Number: 003 • 2020 Pediatric Rheumatology Symposium
Implementing Treat to Target Approach in the Care of Juvenile Idiopathic Arthritis Across a Network of Pediatric Rheumatology Centers
Julia Harris¹, Esi Morgan ², Janalee Taylor ², Tingting Qiu ³, Nancy Griffin ³, Anne Paul ⁴, C. April Bingham ⁵, Danielle Bullock ⁶, Kerry Ferraro ⁷, Mileka Gilbert ⁸, Y. Ingrid Goh ⁹, Olha Halyabar ¹⁰, Karla Jones ¹¹, Melanie Kohlheim ¹², Daniel J. Lovell ¹³, Emily Smitherman ¹⁴, Anjie Vago ⁷, Jennifer Weiss ¹⁵, Cagri Yildirim-Toruner ¹¹, Angela Young ⁷, Michelle Batthish ¹⁶, Beth Gottlieb ¹⁷, Melissa Hazen ¹⁸, Ronald Laxer ¹⁹, Tzielan Lee ²⁰, Melissa Mannion ¹⁴, Judyann Olson ²¹, Michael Shishov ²², Salma Siddique ²³, Charles Spencer ²⁴, Mary Toth ²⁵, Sheetal Vora ²⁶ and Jon Burnham ²⁷, ¹Children's Mercy Kansas City, Overland Park, ²Cincinnati Children's Hospital, Cincinnati, ³Cincinnati Children's Hospital Medical Center, Cincinnati, ⁴Cincinnati Children's Hospital Medical Centre, Cincinnati, ⁵Penn State Children's Hospital, Allentown, ⁶University of Minnesota, Minneapolis, ⁷Pediatric Rheumatology Care and Outcomes Improvement Network, Cincinnati, ⁸Medical University of South Carolina, Charleston, South Carolina, ⁹The Hospital for Sick Children, Toronto, Canada, ¹⁰Children's Hospital/Boston Medical Center, Boston, ¹¹Nationwide Children's Hospital, Columbus, ¹², ¹³Cincinnati, ¹⁴University of Alabama at Birmingham, Birmingham, ¹⁵Hackensack University Medical Center, Hackensack, ¹⁶McMaster University, Hamilton, Canada, ¹⁷Cohen Children's Medical Center, Lake Success, ¹⁸Boston, ¹⁹The Hospital for Sick Children and University of Toronto, Toronto, Canada, ²⁰Stanford Children's, Palo Alto, ²¹Medical College of Wisconsin: Children's Wisconsin, Wauwatosa, Wisconsin, ²²Phoenix Children's Hospital, Phoenix, ²³Nemours/A.I.duPont Hospital for Children, Wilmington, ²⁴Jackson, ²⁵Nemours Foundation, Orlando, ²⁶Atrium Health Levine Children's Hospital, Charlotte, ²⁷Children's Hospital of Philadelphia, Philadelphia
Background/Purpose: In 2018, an international task force published a recommended Treat to Target (T2T) approach to JIA treatment. This treatment paradigm involves setting a treatment…
Abstract Number: 024 • 2020 Pediatric Rheumatology Symposium
Abatacept Treatment Reduces Cutaneous and Joint Activity in Juvenile Localized Scleroderma
Suzanne Li¹, Sarah Ishaq ², Mary Buckley ³, Kathryn Torok ⁴, Barbara Edelheit ⁵, Kaleo Ede ⁶ and C. Egla Rabinovich ⁷, ¹Joseph M. Sanzari Children's Hospital Hackensack Meridian Health, Hackensack, ²Montclair State University, montclair, ³Duke University, Durham, ⁴Pediatric Rheumatology, Univ of Pittsburgh Med Ctr, Pittsburgh, ⁵CT Children's Medical Center, Hartford, ⁶Phoenix Children's Hospital, Phoenix, ⁷Duke University Hospital, Durham
Background/Purpose: Juvenile localized scleroderma (jLS) is an autoimmune disease commonly associated with damage. Damage includes dyspigmentation, tissue atrophy, arthropathy, hemiatrophy, vision loss, and seizures. To…

1
2
3
…
22
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].